Motley Fool Asset Management LLC Takes $1.96 Million Position in ADMA Biologics Inc $ADMA

Posted by Francis Steltz on Jun 11th, 2026

Motley Fool Asset Management LLC bought a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 107,589 shares of the biotechnology company’s stock, valued at approximately $1,962,000.

Several other hedge funds have also bought and sold shares of ADMA. Boothbay Fund Management LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $11,334,000. Tealwood Asset Management Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $1,315,000. American Century Companies Inc. lifted its holdings in shares of ADMA Biologics by 1.8% in the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after acquiring an additional 84,934 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of ADMA Biologics by 14.4% in the 3rd quarter. Public Sector Pension Investment Board now owns 930,800 shares of the biotechnology company’s stock worth $13,646,000 after acquiring an additional 116,867 shares during the last quarter. Finally, First Light Asset Management LLC lifted its holdings in shares of ADMA Biologics by 12.3% in the 3rd quarter. First Light Asset Management LLC now owns 1,069,233 shares of the biotechnology company’s stock worth $15,675,000 after acquiring an additional 117,137 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Up 4.4%

Shares of ADMA Biologics stock opened at $8.48 on Thursday. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. The company’s fifty day simple moving average is $9.21 and its two-hundred day simple moving average is $14.26. The company has a market cap of $1.97 billion, a P/E ratio of 12.47 and a beta of 0.72. ADMA Biologics Inc has a 12-month low of $7.21 and a 12-month high of $22.37.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.19. The business had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.11 EPS. Research analysts anticipate that ADMA Biologics Inc will post 0.84 EPS for the current year.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of recent research reports. Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research note on Wednesday. They issued an “outperform” rating and a $21.00 target price on the stock. Finally, Canaccord Genuity Group decreased their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.67.

Get Our Latest Stock Analysis on ADMA Biologics

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, with a total value of $100,125.00. Following the transaction, the director owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.90% of the company’s stock.

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.